Protandim and the Metabolic Syndrome

Brief Summary

Official Title: “Protandim and the Metabolic Syndrome: A Preliminary Study to Define Protein Signatures That Change Along With Lowered Oxidative Stress Measured as F2 Isoprostanes or TBARS and Inflammation Measured as hsCRP”

Protandim will decrease markers of oxidative stress/inflammation in subjects with metabolic syndrome and proteomics will identify protein profiles that correlate with markers or/changes in oxidative stress.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
  • Study Primary Completion Date: June 2010

Detailed Clinical Trial Description

Evaluate the effects of Protandim on protein profile changes and markers of inflammation and oxidation in subjects (40-60 years of age) with the Metabolic Syndrome.

Interventions Used in this Clinical Trial

  • Dietary Supplement: Protandim
    • The product Protandim used in this study have ingredients derived from five botanical sources [Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)].

Arms, Groups and Cohorts in this Clinical Trial

  • Active Comparator: Protandim
    • one capsule a day for 30 days of protandim given, followed by a wash out period.
  • Placebo Comparator: Placebo
    • one capsule a day for 30 days will be given followed by a washout period.

Outcome Measures for this Clinical Trial

Primary Measures

  • Measure Decrease in Oxidative Stress markers.
    • Time Frame: every 30 days for 120 days
      Safety Issue?: No

Secondary Measures

  • Protein signatures
    • Time Frame: every 30 days for 120 days
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Age = 40-60 years of age
  • Meets at least 3 of the 5 criteria for the metabolic syndrome (as defined by NCEP/ATP III criteria)

NCEP/ATP III criteria

  • Central obesity as measured by waist circumference:
  • Men — Greater than 40 inches
  • Women — Greater than 35 inches
  • Fasting blood triglycerides greater than or equal to 150 mg/dL
  • Blood HDL cholesterol:
  • Men — Less than 40 mg/dL
  • Women — Less than 50 mg/dL
  • Blood pressure greater than or equal to 130/85 mmHg or on anti-hypertensive Rx
  • Fasting glucose greater than or equal to 100 but < 125 mg/dL

Exclusion Criteria

  • Women taking hormone replacement therapy for post menopause
  • Signs or symptoms of acute coronary syndrome
  • History of congestive heart failure (prior myocardial infarction, coronary artery disease including stent placement, coronary artery bypass graft, EBCT calcium score of at least 100, or a positive stress test)
  • Serum creatinine > 1.5 mg/dL, AST or ALT > 2 times ULN, HgA1c >6.5%, severely depressed or elevated blood cell lines, triglycerides > 500, TSH outside of normal range, elevated calcium, blood pressure > 160/100, urine protein > 30 ,g/dl.
  • Concurrent medical conditions/illnesses in which expected life expectancy is 2 years or less and/or are likely to require frequent hospitalizations and treatment adjustments (e.g., cirrhosis, active malignancy, , or highly active rheumatologic condition, lupus, rheumatoid arthritis or chronic obstructive pulmonary disease and diabetes).
  • Participation in any other investigational substance or medical device study within 30 days before this trial and/or participation in such entity during this trial.
  • Known pregnancy.
  • Supplementation with nutraceuticals or if so one month washout before initiating the study before initiating this trial.
  • Taking statins or fibrates to lower cholesterol
  • Inability or unwillingness to provide written informed consent

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 40 Years

Maximum Age for this Clinical Trial: 60 Years

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • SomaLogic, Inc.
  • Collaborator
    • LifeVantage
  • Provider of Information About this Clinical Study
    • Robert H. Eckel, MD; Professor of Medicine, Univeristy of Colorado Denver
  • Overall Official(s)
    • Robert H Eckel, MD, Principal Investigator, University of Colorado, Denver


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: